12/07/2022 Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
NRThe Ministry of Health’s Drug Advisory Committee has not recommended aflibercept, bevacizumab reference biologic (Avastin) or ramucirumab for subsidy for treating metastatic colorectal cancer.
NRBevacizumab (Avastin) has not been recommended in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.
NRAflibercept has not been recommended due to low clinical need and unfavourable cost effectiveness compared with Mvasi.
NRRamucirumab has not been recommended following a request from the manufacturer to not consider it for subsidy.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.